Premium
Survival of patients operated for colorectal liver metastases and concomitant extra‐hepatic disease: External validation of a prognostic model
Author(s) -
Mavros Michael N.,
Hyder Omar,
Pulitano Carlo,
Aldrighetti Luca,
Pawlik Timothy M.
Publication year - 2012
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.23260
Subject(s) - medicine , concomitant , contraindication , concordance , proportional hazards model , cohort , oncology , prognostic model , colorectal cancer , lung , overall survival , disease , gastroenterology , cancer , pathology , alternative medicine
Background The presence of extra‐hepatic disease (EHD) is no longer an absolute contraindication to surgery in patients with colorectal liver metastases (CRLM). Recently, a novel prognostic model predicting overall survival in such patients was proposed using five risk factors (EHD other than isolated lung metastases, CEA ≥10 ng/ml, >5 liver metastases, right colon as the primary CRC location, and diagnosis of EHD concomitant to CRLM recurrence). A bi‐institutional database was used to perform an external validation of this model. Methods Ninety‐seven patients operated for CRLM and EHD between 1982 and 2011 in two institutions was analyzed. The proposed prognostic model was validated in this cohort using Cox proportional hazards models and the concordance index (c). Results Of the five proposed risk factors, only EHD other than isolated lung metastases was found to independently predict overall survival [Hazards Ratio (HR) = 2.10 (95% CI: 1.01–4.40)]. Although, the number of risk factors was marginally associated with overall survival in univariate analysis ( P = 0.049), the performance of the proposed prognostic model was poor when applied to our cohort (c = 0.64). Conclusion The examined prognostic model of survival in patients with CRLM and EHD had poor performance. Further research is warranted to delineate the subset of patients who will benefit from surgery. J. Surg. Oncol. 2013;107:481–485. © 2012 Wiley Periodicals, Inc.